OncLive - Clinical Oncology News, Cancer Expert Insights
OncLive - Clinical Oncology News, Cancer Expert Insights
Spotlight
The OncLive Insider app is live!CME Opportunities
Specialty
View MoreBreast CancerLung CancerGastrointestinal CancerGenitourinary CancersOvarian CancerProstate CancerMelanoma & Skin CancerMCLMPNCAR T-cell TherapyChronic Lymphocytic LeukemiaGynecologic OncologyHematologic OncologyImmuno-OncologyMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
PartnersPublications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker ConsortiumSubscribe
  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information

© 2025 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Spotlight
  • The OncLive Insider app is live!
  • CME Opportunities
SpecialtySee All >
  • Breast Cancer
  • Lung Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Ovarian Cancer
  • Prostate Cancer
  • Melanoma & Skin Cancer
  • MCL
  • MPN
  • CAR T-cell Therapy
  • Chronic Lymphocytic Leukemia
  • Gynecologic Oncology
  • Hematologic Oncology
  • Immuno-Oncology
  • Multiple Myeloma
  • Urothelial Cancer
OncLive SOSS
  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Gilberto De Lima Lopes, MD

  1. home

Articles

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

May 21st 2020

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

May 20th 2020

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLC

May 15th 2020

Gilberto De Lima Lopes, MD, discusses the FDA approval of nivolumab (Opdivo) and ipilimumab (Yervoy) in non–small cell lung cancer (NSCLC).

Dr. Lopes on Standard Durations of Checkpoint Inhibition in Metastatic Lung Cancer

February 9th 2020

Gilberto De Lima Lopes, MD, discusses the standard of care for pembrolizumab in patients with metastatic lung cancer.